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Abstract 
While Australo-Papuan death adder neurotoxicity is generally considered to be 
due to the actions of reversible competitive postsynaptic 〈-neurotoxins, the neurotoxic 
effects are often poorly reversed by antivenom or anticholinesterases. This suggests 
that the venom may contain a snake presynaptic phospholipase A2 (PLA2) neurotoxin 
(SPAN) that binds irreversibly to motor nerve terminals to inhibit neurotransmitter 
release. Using size-exclusion liquid chromatography under non-reducing conditions, 
we report the isolation and characterisation of a high molecular mass SPAN complex, 
P-elapitoxin-Aa1a (P-EPTX-Aa1a), from the venom of the common death adder 
Acanthophis antarcticus. Using the chick biventer cervicis nerve-muscle preparation, 
P-EPTX-Aa1a (44,698 Da) caused inhibition of nerve-evoked twitch contractions 
while responses to cholinergic agonists and KCl remained unaffected. P-EPTX-Aa1a 
also produced significant fade in tetanic contractions and a triphasic timecourse of 
neuromuscular blockade. These actions are consistent with other SPANs that inhibit 
acetylcholine release. P-EPTX-Aa1a was found to be a heterotrimeric complex 
composed of 〈-, ®- and ©-subunits in a 1:1:1 stoichiometry with each subunit 
showing significant N-terminal sequence homology to the subunits of taipoxin, a 
SPAN from Oxyuranus s. scutellatus. Like taipoxin, only the 〈-chain produced any 
signs of neurotoxicity or displayed significant PLA2 enzymatic activity. Preincubation 
with monovalent death adder antivenom or suramin, or inhibition of PLA2 activity by 
incubation with 4-bromophenacyl bromide, either prevented or significantly delayed 
the onset of toxicity by P-EPTX-Aa1a. However, antivenom failed to reverse 
neurotoxicity. Early intervention with antivenom may therefore be important in severe 
cases of envenomation by A. antarcticus, given the presence of potent irreversible 
presynaptic neurotoxins. 
 
Keywords: Presynaptic snake neurotoxin; SPAN; death adder; Acanthophis 
antarcticus; taipoxin; phospholipase A2 
 
1. Introduction 
The Elapidae family consists of a variety of highly venomous snakes, many of 
which are found in Australia. The common death adder Acanthophis antarcticus 
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(Serpentes: Elapidae: Acanthophiinae) is usually found in the coastal areas of the 
states of Queensland, New South Wales (NSW), South Australia and Western 
Australian [1, 2] and is considered an elapid, despite its viper-like appearance and 
behaviour. Other Acanthophis spp. have also been identified in Irian Jaya, Papua 
New Guinea and some eastern Indonesian islands [2]. Symptoms of envenomation 
from Acanthophis mainly involve neurotoxic symptoms, including ptosis and general 
flaccid muscle paralysis, with death resulting from respiratory failure [2, 3]. Although 
some cases of weak haemolytic and anticoagulant activity have been reported [4, 5], 
there have been no serious clinical cases of coagulopathies resulting from 
envenomation, as is common with bites from many other venomous Australian elapid 
snakes. Envenomation does not produce any clinical signs of myotoxicity, with 
studies confirming that there is no evidence of skeletal muscle damage [6, 7]. More 
recent studies have found myotoxicity present in the directly-stimulated chick biventer 
cervicis nerve-muscle (CBCNM) preparation after incubation with some species of 
death adder, however A. antarcticus whole venom was devoid of myotoxic activity 
[8]. Significantly, delayed-onset neurotoxicity is a problem in death adder 
envenomations, occasionally with late presentation of neurotoxicity as the first feature 
of envenoming [2, 9, 10]. This has resulted in a recommended hospital admission 
period of 24 hours for patients in Papua New Guinea and both central and northern 
Australia, and for children in any region [11]. 
The recommended primary treatment for death adder envenomation is CSL 
monovalent death adder antivenom, which has been raised against A. antarcticus 
venom [12, 13], although cross-neutralisation occurs with ‘monovalent’ taipan and 
brown snake antivenoms [14]. Death adder antivenom appears to be quite effective 
in preventing the progression of neurotoxicity from all species of death adder in 
Australia and Papua New Guinea [2, 3], showing a rapid reversal of paralysis. 
However, some reports have suggested that the neurotoxic effects can be poorly 
reversed by antivenom or anticholinesterase (neostigmine) if the patient presents late 
after envenomation [15]. In support, an in vitro study involving A. antarcticus, A. 
praelongus and A. pyrrhus venoms found that all three venoms produced rapid 
postsynaptic neurotoxicity but antivenom displayed varying efficacy to reverse toxicity 
following neuromuscular blockade over a 4 hour period. Indeed, there was only a 
22% recovery of contractile responses following complete neuromuscular blockade 
with A. antarcticus, the venom to which the antivenom is raised [16].  
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Acanthophis venoms have long been considered to be composed of 
predominantly postsynaptic 〈-neurotoxins (for a review see [17]). However, rapidly 
developing neurotoxicity from postsynaptic 〈-neurotoxins conceals the action of any 
underlying snake presynaptic phospholipase A2 (PLA2; EC 3.1.1.4) neurotoxins (so-
called ‘β-neurotoxins’ or SPANs), that bind to motor nerve terminals to inhibit 
neurotransmitter release [18], or myotoxins that may be present in the venom. These 
toxins typically have slower onsets of activity but bind irreversibly [19, 20]. In the case 
of patients with delayed-onset or slowly-developing neurotoxicity, SPANS or 
myotoxins may play a significant role in the speed of recovery following antivenom 
therapy due to the irreversible nature of their actions, and may go some way to 
explain the above resistance to antivenom therapy. While a number of monomeric 
PLA2 (12–15 kDa) proteins have been isolated from death adder venom (for a review 
see [17]), none of these have been characterized pharmacologically. Recently, 
however, we identified the presence of high molecular mass presynaptic neurotoxic 
fractions within the venom of A. antarcticus geographic variants and other Australo-
Papuan Acanthophis spp. [21]. This study therefore aimed to biochemically and 
pharmacologically characterise the high molecular mass SPAN complex present 
within A. antarcticus (NSW variant) venom. 
 
2. Materials and methods 
2.1. Venom / toxin preparation and storage 
Lyophilized pooled A. antarcticus venom (NSW variant) was provided by the 
Australian Reptile Park (Gosford, NSW). Death adders were collected from their 
natural habitats in the Sydney metropolitan region. To minimise the effects of 
individual variations in venom [22], venom was collected, pooled and lyophilised (100 
mg dry weight) by the supplier. Lyophilised venom and isolated components were 
stored at –20oC until required.  
 
2.2. Size-exclusion liquid chromatography under non-reducing conditions 
Bioassay-guided isolation of the high molecular mass SPAN complex using fast-
perfusion liquid chromatography of whole venom was performed using a Superdex 
G-75 column (10 x 300 mm, 13 µm; GE Healthcare, Sydney, NSW, Australia) 
employing methods described previously [21]. The purified SPAN complex was rerun 
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under the same conditions to ensure purity. The approximate molecular mass of the 
SPAN complex was then determined following calibration of the Superdex G-75 
column with protein standards ranging from 6.5 to 66 kDa, as described previously 
[21]. The void volume (Vo) of the column was determined by running blue dextran 
(2,000 kDa), and the elution volume (Ve) was calculated for each molecular mass 
marker. The molecular mass range of SPAN complexes were then determined from 
interpolation of a plot of log molecular mass versus retention ratio (Ve / Vo) of the 
standards. 
 
2.2.2. Reverse-phase high-pressure liquid chromatography (RP-HPLC) 
Subunits of the high molecular mass SPAN complex were isolated from the 
purified size-exclusion fraction using a Chromolith RP-18e column (4.6 x 100 mm; 
Merck KGaA, Darmstadt, Germany). Fractions were eluted using an 
acetonitrile/trifluoroacetic acid (TFA) gradient (Buffer A: 0.1% [v/v] TFA, Buffer B: 
acetonitrile / 0.085% [v/v} TFA). The gradient employed was: 0–10 min, 2% B; 10–50 
min, 2–98% B; at a flow rate of 4 ml/min. The eluant was monitored at 280 and 214 
nm.  
 
2.3 Bicinchoninic Acid Protein (BCA) Assay 
Following lyophilisation, protein concentrations were determined using the 
Quantipro™ BCA assay kit (Sigma-Aldrich). Protein contents between 5–200 µg/ml 
were detected at 560 nm by a Titertek Multiscan Plus MKII plate reader (Flow 
Laboratories Australasia, North Ryde, NSW). A standard curve was created using 
bovine serum albumin from which protein concentrations were interpolated. 
 
2.4. Mass determination of toxin subunits 
2.4.1. Matrix-assisted laser desorption ionisation time-of-flight (MALDI-TOF) mass 
spectrometry 
Lyophilised RP-HPLC samples were analysed to determine mass and confirm 
purity using a Shimadzu AXIMA TOF2 (Shimadzu Oceania, Rydalmere, NSW, 
Australia). The system was operated in positive linear mode. Sinapinic acid (20 
mg/ml in 40% acetonitrile, 0.1% TFA) was used as the matrix. Samples were 
resuspended in 50% [v/v] acetonitrile, 1% [v/v] TFA and spotted with an equal 
volume of matrix, then allowed to dry.  Data was collected with a 337 nm nitrogen 
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laser. The signal was averaged and processed using Shimadzu Launchpad 2.7 
software (Shimadzu Oceania, Rydalmere, NSW, Australia). All spectra were 
calibrated externally with appropriate protein standard mixtures (insulin, 5,729.61 Da; 
cytochrome c, 12,361.96 Da and apomyoglobin, 16,952.27 Da). 
 
2.4.2. Electrospray ionisation quadrupole time-of-flight (ESI-Q-TOF) mass 
spectrometry 
Once purity was confirmed, the definitive mass of RP-HPLC samples was 
determined using a QSTAR Elite hybrid Q-TOF mass spectrometer system (Applied 
Biosystems/MDS Sciex, Foster City, CA, USA) equipped with a nanospray source. 
Lyophilised samples were dissolved into 10 µL of solvent A (2% [v/v] acetonitrile, 
0.2% [v/v] formic acid) and were loaded into an Eksigent AS-1 autosampler 
connected to a Tempo nanoLC system (Eksigent Technologies, Dublin, CA, USA). 
Sample was passed into a C18 reverse-phase trap column (Michrom Bioresources, 
Auburn, CA, USA) connected to a 10-way switching valve at a flow rate of 20 µL/min, 
and the trap was washed for 3 minutes. Proteins were eluted from the trap at a flow 
rate of 500 nL/min, and then flowed into a New Objective IntegraFrit column (100 
mm, 75 µm ID) packed with ProteoPep 2 C18 resin. At the moment of switching, an 
acetonitrile gradient was initiated (Solvent A: 2% [v/v] acetonitrile, 0.2% [v/v] formic 
acid. Solvent B: 98% [v/v] acetonitrile, 0.2% [v/v] formic acid. Gradient: 0–30 min, 5–
95% B; 30–32 min, 95% B; 32–35 min, 95–5% B; 35–45 min, 0% B) to elute bound 
protein from the column. Eluted proteins flowed into a MicroIonSpray II-mounted 75 
µm ID emitter tip that tapered to 15 µm. Charged proteins were then ionised by 
nanoelectrospray with a potential of 2300 V into the source of the QSTAR with a 
temperature of 150°C. A mass range of 500–2000 Da was scanned every second. 
The masses of proteins were determined as an average of the masses of multiply 
charged ions. Raw data were processed using the Analyst® QS version 2.0 (Applied 
Biosystems/MDS Sciex, Foster City, CA, USA).  
 
2.5. N-terminal sequence determination 
N-terminal sequencing of purified toxin subunits was performed by the 
Biomolecular Research Facility at the University of Newcastle, NSW, Australia using 
an Applied Biosystems Procise HT Protein Sequencer, and the Australian Proteome 
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Analysis Facility (APAF) using an Applied Biosystems/Perkin-Elmer Procise 494 
Procise protein sequencer. Samples was loaded onto a biobrene-treated, precycled 
discs and subjected to N-terminal (Edman) sequencing. Sequence homology of 
purified toxin subunits with existing proteins was determined using a Blastp search of 
the UniProt Knowledgebase (http://ca.expasy.org/tools/blast) followed by a ClustalW 
multiple alignment.  
 
2.6. Isolated chick biventer cervicis nerve-muscle preparation 
Isolated fractions were tested for neurotoxic and myotoxic activity using the 
isolated chick biventer cervicis nerve-muscle (CBCNM) preparation [23]. Male 
Australorps chicks aged 1–7 days were euthanised with CO2 and exsanguinated. The 
biventer cervicis muscle with attached nerve was dissected and placed in an organ 
bath (8 ml) under 1 gram of resting tension. The organ bath contained Krebs-
Henseleit solution of the following composition (in mM): NaCl, 118.4; KCl, 4.7; 
MgSO4, 1.2; KH2PO4, 1.2; NaHCO3, 25.0; D-glucose, 11.1; CaCl2, 2.5, which was 
bubbled with carbogen (95% O2 and 5% CO2) and maintained at 34°C. Indirect 
stimulation was applied to the motor nerve using supramaximal ca. 30 V square-
wave pulses of 0.2 ms duration at 0.1 Hz with a Grass S88 stimulator. Contractions 
were measured using an isometric force transducer (ADInstruments, Belle Vista, 
NSW, Australia). The nerve-evoked muscle tissue was allowed to equilibrate for 30 
minutes. Exclusive electrical stimulation of the nerve was ensured by complete 
blockade of twitches using 10 µM d-tubocurarine. Washout was then repeated until 
twitch tension returned to its original amplitude. Contractures to various exogenous 
agonists were subsequently recorded in the absence of electrical stimulation before, 
and after, incubation with toxin. The final bath concentrations and periods of 
incubation were as follows: acetylcholine (ACh, 1 mM) for 30 s; carbachol (CCh, 20 
µM) for 60 s; potassium chloride (KCl, 40 mM) for 30 s [24]. After each agonist 
incubation period, washout was repeated until a stable baseline was observed. 
Following addition of toxin, twitch tension amplitude was monitored for 4 hours, or 
until twitches were abolished. Time-matched or vehicle controls confirmed that 
muscle fatigue was not significant up to 4 hours after introduction of muscles into the 
organ bath. Muscle tension from isometric force transducers was amplified using a 
ML221 bridge amplifier (ADInstruments) and recorded using a Powerlab 2/25 system 
(ADInstruments) connected to a Macintosh computer. Data was digitised at 140 Hz, 
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modified with a 50/60 Hz mains filter and a 20–200 Hz low-pass filter. Muscle tension 
was recorded using Chart v5.5.4 software (ADInstruments).  
 
2.6.1. Antivenom and suramin reversibility studies 
The efficacy of monovalent death adder antivenom (CSL Biotherapies, 
Melbourne, Australia) or suramin to neutralise the activity of the toxin was assessed 
by preincubating the organ bath with 5 U/ml of antivenom or 0.3 mM suramin for 10 
min prior to addition of venom or toxin. Reversibility studies were also performed by 
the addition of 5 U/ml monovalent death adder antivenom at 90% inhibition of twitch 
contractions (t90) or 0.3 mM suramin at 50% inhibition of twitch contractions (t50). An 
additional study observed the reversibility of toxicity using suramin (0.3 mM) after the 
toxin was incubated for 30 min and then washed from the bath.  
 
2.6.2. Myotoxicity studies 
The myotoxic effects of venom or toxin were examined using direct stimulation of 
the biventer cervicis muscle. Muscles were directly stimulated every 10 s with square 
wave pulses of 2 ms duration at supramaximal voltage (ca. 30 V) using electrodes 
placed around the belly of the muscle. Muscle contractions due to any nerve-evoked 
release of ACh were blocked by the addition of 10 µM d-tubocurarine, which 
remained in the organ bath for the duration of the experiment. Toxin was left in 
contact with the preparation until blockade of twitch contractions occurred, or for a 
270 min period. Venom or toxins were considered to be myotoxic if they inhibited 
twitches elicited by direct stimulation or caused an Increase in baseline muscle 
tension [24]. 
 
2.6.3. Low quantal content studies 
The presence of Mg2+ in the bathing solution facilitates a more pronounced 
triphasic action of SPANs on twitch contractions [25, 26]. The safety margin for 
neurotransmitter release was therefore reduced in separate experiments by the 
addition of 9–17 mM Mg2+ to the bath [27]. Increasing concentrations of MgCl2 were 
titrated to suppress twitch contractions to between 10-30% of initial amplitude. After 
twitch contractions had stablised for at least 30 min toxin was then added. 
 
2.6.4. Tetanic fade studies 
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In separate experiments, the ability of the CBCNM preparation to maintain tetanic 
contractions in response to a short tetanic train of stimuli in the presence of the toxin 
was investigated. Prior to, and following, addition of toxin to the bath, three 50 Hz, 3 s 
trains every 10 s were interspersed at 0% (control), 25% (t25), 50% (t50), 75% (t75) 
and 90% (t90) neuromuscular blockade. These tetanic trains were interspersed 
between normal 0.05 ms 10 Hz stimulation. The amount of fade in the tetanic 
response was calculated by comparing the amplitude of the initial (tinitial) and final 












)  Equation 1 
 
2.7. Secretory phospholipase A2 (sPLA2) activity assay 
The sPLA2 activities of whole venom and isolated toxins were determined using a 
colorimetric sPLA2 assay kit (Cayman Chemical Ltd, Ann Arbor, MI) as previously 
described [21]. sPLA2 activity was calculated as micromoles of substrate (1,2-dithio 
analog of diheptanoyl phosphohatidylcholine) hydrolysed per minute per milligram of 
enzyme (µmol/min/mg), with bee (Apis mellifera) venom as a positive control. 
 
2.8. Chemical modification of His48 using 4-bromophenacyl bromide 
The PLA2 enzymatic activity of the toxin was inhibited by alkylation of the His48 
residue using 4-bromophenacyl bromide (4BPB) as previously described [28]. 330 µg 
of toxin was prepared in 615 µL of 0.1 M Tris-HCl / 0.7 M EDTA buffer (pH 8.0), to 
which 10 µL of 4BPB (0.75 mg/ml in ethanol) was subsequently added, and 
incubated at 25°C for 13 hrs. The modified toxin was collected and lyophilised prior to 
assaying for sPLA2 activity and neurotoxicity.  
 
2.9. Chemicals and drugs 
Unless otherwise stated, all chemicals and drugs were purchased from Sigma-
Aldrich, Castle Hill, NSW, Australia. 
 
2.10. Data analysis 
Twitch contraction amplitude was expressed as a percentage of initial amplitude, 
prior to addition of the toxin. Contractile responses to exogenous agonists were 
 B. Blacklow et al./Biochemical Pharmacology  11 
expressed as a percentage of their amplitude prior to addition of the toxin. To 
compare the neurotoxicity of venoms, the time taken to cause 90% inhibition of 
nerve-mediated twitch contractions (t90) was determined as a quantitative measure of 
potency. Values for t90 were calculated for each experiment by determining the 
elapsed time after toxin addition at 10% of the initial twitch contraction amplitude, and 
then the means and standard error of the means were calculated. Where indicated, 
statistical significance was determined by one-way analysis of variance (ANOVA) or 
paired Student’s t-test. All ANOVAs were followed by a Bonferroni-corrected multiple 
t-test. Statistical analyses were performed using the PRISM 5.0 software package 




3.1. Toxicity of whole venom 
Whole A. antarcticus venom (10 µg/ml) produced rapid and complete inhibition of 
nerve-evoked twitch contractions within 9 ± 1 min (n = 2; Fig. 1A), whereas with time-
matched controls there was no significant fatigue of twitch tension over a 240 min 
period (Fig. 1A). Whole A. antarcticus venom displayed classical postsynaptic 
neurotoxic activity, with complete inhibition of responses to exogenous nicotinic 
agonists (p < 0.001, n = 2; Fig. 1D).  
 
3.2. Venom fractionation under non-denaturing conditions 
Prior to separation of whole A. antarcticus venom by size-exclusion FPLC the 
Sephadex G-75 column was calibrated using a set of molecular weight markers. 
Using blue dextran (2,000 kDa), the void volume (Vo) of the Sephadex G-75 column 
was determined to be 7.6 ml while the elution volume (Ve) of a range of known 
standards was determined and the molecular mass of unknown complexed was then 
determined by interpolation of a plot of log molecular mass vs. Ve / Vo ratio (Fig 2B). 
Under non-reducing conditions, fractionation of whole A. antarcticus venom produced 
a characteristic pattern of four major peaks (Fig. 2A). This was similar to that seen 
with other geographic variants of A. antarcticus and certain other Australo-Papuan 
species of Acanthophis [21]. The retention time of the earliest eluting fraction was 
12.8–16.0 min, with the peak absorbance at 14.6 min (Fig. 2A), corresponding to a 
molecular mass of ca. 43 kDa (Fig. 2B). 
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SPAN complexes typically have molecular weights ranging between 21 kDa (the 
covalently-linked heterodimer β-bungarotoxin from Bungarus fasciatus; [29]) and ca. 
87 kDa (the heterohexameric textilotoxin; [30]). Therefore the 43 kDa fraction was 
collected for further biochemical characterisation and neurotoxicity testing. The yield 
of the early eluting fraction, as determined by BCA assay, was 6.5% w/w A. 
antarcticus venom (195 µg from ca. 3 mg of whole venom). Toxicity screening in the 
CBCNM preparation indicated that this contained prejunctional neurotoxic activity 
(see section 3.3), while the second peak (eluting at 17.4–21.5 min, ca. 3–13 kDa) 
caused a postsynaptic neurotoxic action due to inhibition of responses to the 
exogenous nicotinic agonists, ACh and CCh (data not shown). Accordingly, the 43 
kDa fraction was named P-elapitoxin-Aa1a (P-EPTX-Aa1a) using the rational 
nomenclature system for naming toxins from spiders and other venomous animals 
[31]. The activity descriptor prefix ‘P’ indicates SPANs with a presynaptic action to 
inhibit neurotransmitter release, ‘elapitoxin’ is the generic name for toxins from the 
family Elapidae, ‘Aa’ are the genus and species descriptor for Acanthophis 
antarcticus, ‘1’ represents the first family of toxins with this activity (‘1’ was chosen to 
represent multimeric SPANs vs. ‘2’ for monomeric SPAN), and ‘a’ denotes the first 
paralog (isoform) found. 
 
3.3. Neurotoxicity studies with P-EPTX-Aa1a 
P-elapitoxin-Aa1a (55–222 nM) produced a concentration-dependent inhibition of 
nerve-evoked twitch contractions of the CBCNM preparation (Fig. 1B). The t90 value 
for 222 nM P-EPTX-Aa1a for inhibition of twitch contractions was 74 ± 3.5 min (n = 4) 
that increased to 121 ± 7 min (n = 4) using 55 nM P-EPTX-Aa1a. A slight triphasic 
timecourse of action characterized by depression-enhancement-blockade of 
neurotransmission was evident as has been previously reported for a variety of other 
SPANs in mammalian nerve-muscle preparations [19, 32]. This triphasic action was 
appreciably enhanced under conditions of low quantal content (high external [Mg2+]), 
and the t90 value for inhibition of twitch contractions was also significantly reduced to 
41 ± 1 min (p < 0.001, unpaired Student’s t-test, n = 3; Fig. 3A). 
Importantly, following complete neuromuscular blockade, P-EPTX-Aa1a failed to 
inhibit responses to the exogenous cholinergic agonists ACh and CCh or the 
depolarising agonist KCl (n = 4; Fig. 1D). Interestingly, the responses to carbachol 
were enhanced in many fractions, but this has been previously reported in this 
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preparation [33-35] and may reflect time-dependent sensitization of the tissue to 
carbachol. Furthermore, P-EPTX-Aa1a failed to induce any significant change in 
baseline tension (data not shown) or directly-stimulated muscle twitches of the 
biventer cervicis muscle (n = 4; Fig. 1C). These actions are consistent with the 
presence of a SPAN complex that inhibits neurotransmitter release without any 
additional signs of myotoxicity.  
Further support that P-EPTX-Aa1a is a SPAN complex was provided by the 
ability of the toxin to induce fade in tetanic contractions that contributes to muscle 
fatigue at more physiological frequencies of nerve stimulation (Fig. 3B and C). 
Tetanic fade in controls in response to a 3 sec 50 Hz train was minimal in all 
experiments with a range of 0–6% (1 ± 1%, n = 7). In the presence of the positive 
control, 1 µM d-tubocurarine, isometric tension rapidly faded to a plateau level. With 
P-EPTX-Aa1a and taipoxin tetanic fade developed gradually in the initial 500 ms to 
1000 ms of the tetanic train to a plateau that was maintained to the end of the train 
(Fig. 3B). P-EPTX-Aa1a (55 nM) produced concentration-dependent tetanic fade of 
53 ± 11% at t75 (n = 4; Fig. 3C). This was less than the positive control, 1 µM d-
tubocurarine (87 ± 11% at t75, n = 4), but greater than the classical heterotrimeric 
SPAN, taipoxin (32 ± 14% at t75, n = 4, 55 nM) previously shown to cause tetanic 
fade [36]. Interestingly, lower concentrations produced a greater degree of tetanic 
fade (n = 4; Fig. 3C).  
 
3.4. Neutralisation and reversibility of P-EPTX-Aa1a neurotoxicity 
CSL Monovalent death adder antivenom (5 U/ml) was effective in preventing the 
development of toxicity with P-EPTX-Aa1a (Fig. 1B). However, reversal of P-EPTX-
Aa1a toxicity by antivenom applied at t90 was unsuccessful (Fig. 1B), highlighting the 
irreversible binding of SPANs. Preincubation with the polysulphonated naphthylurea 
anti-trypanosomal drug, suramin (0.3 mM), previously shown to inhibit SPAN but not 
postsynaptic α-neurotoxin toxicity [37, 38] produced a 4.3-fold increase in the time to 
t90 of P-EPTX-Aa1a to 315 ± 51 min (p < 0.01, n = 4), but unfortunately failed to 
completely inhibit neuromuscular blockade (Fig. 4). The Irreversible nature of toxin 
binding following only short incubation periods [19, 39] was further highlighted by 
experiments where unbound toxin was washed from the bath after 30 min but 
neuromuscular blockade still occurred despite subsequent addition of 0.3 mM 
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suramin (t90 = 119 ± 7.2 min, n = 4; Fig. 4). Suramin administered at t50 was even 
less effective at reversing neurotoxicity with 90% neuromuscular blockade reached at 
146 ± 37 min (n = 4; Fig. 4). Consistent with its prejunctional action, agonist 
responses were not significantly inhibited following application of antivenom or 
suramin in the above experiments (Fig. 1D). 
 
3.5 Fractionation of the P-EPTX-Aa1a complex 
Given that SPAN complexes are commonly derived of between 2 and 6 subunits 
[30, 40], P-EPTX-Aa1a subunits were separated under reducing conditions using 
C18 RP-HPLC to determine the subunit composition. This resulted in three major 
peaks (Fig. 5A). The BCA protein assay failed to detect any significant quantities of 
protein in the early eluting peak at 9.6–10.1 min, and this peak was subsequently 
excluded from further investigation. The three most abundant peaks, eluting at 16.7, 
10.8, and 17.3 min, were named the 〈-, β-, and ©-subunits of P-EPTX-Aa1a, 
respectively, based on their homology to the molecular masses (see section 3.5) and 
N-terminal amino acid sequences (see section 3.6) of known multimeric SPAN 
subunits.  
 
3.6. Mass spectrometry of P-EPTX-Aa1a subunits 
ESI-Q-TOF mass spectrometry determined the definitive mass of the α- and β-
subunits to be 13,809 Da and 13,516 Da, respectively (Figs. 5B and C). MALDI-TOF 
mass spectrometry determined that the ©-subunit was most likely heterogeneously 
glycosylated with a nominal mass of 17,373 Da (Fig. 5D). The sum of the 〈-, ®- and 
©-subunit masses resulted in an average mass of 44,698 Da, which is comparable 
with the mass estimated from calibration of the size-exclusion column (ca. 43 kDa), 
suggesting a 1:1:1 binding stoichiometry. 
 
3.7. N-terminal sequencing of P-EPTX-Aa1a subunits 
Partial N-terminal sequences of the 〈-, ®-, and ©-subunits were determined by 
Edman degradation. The α- and β-subunits showed a high degree of homology to 
each other but the γ-subunit possessed a seven residue extension at the N-terminus 
(Fig. 6A). All three subunits were then subjected to a Blastp analysis of the UniProt 
Knowledgebase and found to show significant homology to a range of SPAN 
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neurotoxin subunits (Fig. 6B). Comparing the three subunit sequences with 
corresponding N-terminal fragments of other snake proteins, the subunits of P-EPTX-
Aa1a displayed the highest overall homology to the heterotrimeric SPAN taipoxin 
from the coastal taipan Oxyuranus s. scutellatus [41], with the 〈-, ®- and ©-chains of 
taipoxin showed 85%, 87% and 90% homology to the corresponding subunits of P-
EPTX-Aa1a. Individual subunits of P-EPTX-Aa1a also showed lesser homology to 
subunits of the heteromultimeric SPANs cannitoxin from Oxyuranus s. canni [35] and 
textilotoxin from Pseudonaja textilis [42]. 
 
3.8 Neurotoxicity studies with P-EPTX-Aa1a subunits 
Of the three subunits isolated from P-EPTX-Aa1a, only the 〈-subunit (740 nM) 
produced inhibition of nerve-evoked twitch contractions compared with the time-
matched control, resulting in 79 ± 10% neuromuscular blockade after 270 min (n = 4; 
Fig. 7A). This neuromuscular blockade occurred in the absence of any significant 
inhibition of responses to exogenous agonists (Fig. 7C). There was a complete lack 
of toxicity apparent with both ®- and γ-subunits at this high concentration. Equimolar 
recombination of these subunits determined that the 〈-subunit was important in 
presenting any significant toxicity, as ®- and γ-subunits (150 nM) combined only 
caused incomplete inhibition of twitch contractions with only 51 ± 7% neuromuscular 
blockade after 270 min (Fig. 7B). The equimolar recombination of the 〈- and γ-
subunits (150 nM) caused some inhibition of twitch responses with 73 ± 13% 
neuromuscular blockade at 270 min (n = 4) while the recombination of the 〈- and β-
subunits (150 nM) resulted in complete neuromuscular blockade with a t90 value of 
149 ± 6 min (n = 4; Fig. 7B). The equimolar recombination of all 3 subunits (150 nM) 
produced the most rapid inhibition of twitches (t90 = 114 ± 7 min, n = 4; Fig. 7B), 
which was slower in comparison to the whole P-EPTX-Aa1a complex (one-way 
ANOVA, p < 0.05) but significantly more rapid than with the 〈-subunit alone. Finally, 
no individual P-EPTX-Aa1a subunit or recombined subunits inhibited agonist 
responses (Fig. 7C). 
 
3.9 Secretory phospholipase A2 (sPLA2) activity 
The sPLA2 activity of whole A. antarcticus venom and P-EPTX-Aa1a was 
determined to be 257 ± 14 µmol/min/mg and 400 ± 52 µmol/min/mg, respectively (n = 
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4; Fig 8A). In comparison, the sPLA2 activity of the positive control, Apis mellifera bee 
venom, was 287 ± 10 µmol/min/mg (n = 18). The 〈-subunit also displayed appreciable 
PLA2 activity of 211 ± 17 µmol/min/mg (n = 6) while the ®- and ©-subunits did not 
exhibit any significant PLA2 activity (n = 3). 
 
3.10 Chemical modification of histidine residues of P-EPTX-Aa1a using 4-
bromophenacyl bromide 
Modification of histidines residues in P-EPTX-Aa1a using 4BPB reduced the 
PLA2 activity to 20 µmol/min/mg, equivalent to ca. 5% of the original P-EPTX-Aa1a 
complex (Fig. 8A). This is most likely the result of alkylation of a His48 residue 
previously identified at the active site of snake PLA2 toxins [43]. Alkylated P-EPTX-
Aa1a caused significantly reduced toxicity in the CBCNM preparation, with only a 13 
± 3.2% reduction in twitch responses at 240 min (n = 4; Fig. 8B). This occurred in the 
absence of any reduction in responses to exogenous agonists (data not shown). The 
vehicle (4BPB) had no effect on twitch tension or agonist responses (Fig. 8B). 
 
4. Discussion 
While the venom of A. antarcticus displays classical postjunctional neurotoxicity, 
and is known to contain a number of long- and short-chain postsynaptic 〈-neurotoxins 
[17], the present study clearly identifies the presence of a heterotrimeric SPAN 
complex. To our knowledge, P-EPTX-Aa1a represents the first SPAN complex to be 
biochemically and pharmacologically characterised from the venom of A. antarcticus. 
P-EPTX-Aa1a caused concentration-dependent inhibition of neuromuscular 
transmission, with no reduction of contracture responses to nicotinic cholinergic 
agonists, consistent with a prejunctional action to block ACh release. Some 
monomeric SPAN neurotoxins such as notexin also have myotoxic activity [44] but 
the absence of any effect on responses to KCl and direct muscle stimulation are 
consistent with P-EPTX-Aa1a acting as a presynaptic neurotoxin lacking myotoxicity. 
P-EPTX-Aa1a also produced a pronounced triphasic action, particularly under 
conditions of low quantal content, characterised by an initial brief depression, 
followed by a period of increased tension, and then a gradual decline to complete 
neuromuscular blockade. This is typical of SPANs including β-bungarotoxin [45], 
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taipoxin [46], notexin [47] and crotoxin [48], especially under conditions of high 
[Mg2+]o [25, 26]. 
Under non-denaturing conditions the molecular mass of the P-EPTX-Aa1a 
complex was determined as ca. 43 kDa following separation of the SPAN on a size-
exclusion column. Subsequent RP-HPLC of P-EPTX-Aa1a produced three major 
subunits whose combined masses, 44,698 Da, was in close agreement with the 
molecular mass of the SPAN complex estimated from size-exclusion 
chromatography. Masses and N-terminal sequences of all three P-EPTX-Aa1a 
subunits were similar to those found in the heterotrimeric SPAN complexes taipoxin, 
cannitoxin and to a lesser extent textilotoxin [35, 42]. MALDI-TOF mass spectrometry 
revealed the ©-subunit of P-EPTX-Aa1a to be a glycoprotein as evidenced by the 
areas of heterogenous glycosylation observed in the MALDI spectra. Glycosylation 
was also described for ©-subunits of previously isolated heterotrimeric SPAN 
complexes such as taipoxin [41], cannitoxin [35], and paradoxin [49].  
Similar to other heterotrimeric SPAN complexes, only the α-subunit of P-EPTX-
Aa1a presented any significant PLA2 or neurotoxic activity, likely contributing 
significantly to the overall toxicity of the complex. Unfortunately it is difficult to 
compare PLA2 activity between studies as assay conditions vary considerably. 
However, using the same colourimetric assay, cannitoxin was found to possess a 
similar pattern of high PLA2 activity in the whole complex and α-subunit, albeit at a 
lower activity than P-EPTX-Aa1a [35]. Furthermore the lack of PLA2 activity with the 
β- and γ-subunits of P-EPTX-Aa1a was mirrored in the cannitoxin study. Despite 
lacking any significant neurotoxic or enzyme activity all three subunits of P-EPTX-
Aa1a appear to be necessary for maximum neurotoxicity, with equimolar 
recombination of all subunits yielding close to the same neurotoxicity as the native P-
EPTX-Aa1a complex. This duplication of homologous subunits possibly reflects an 
evolutionary approach to increase the affinity of the SPAN complex for its 
prejunctional target and hence its neurotoxicity [50]. This is perhaps because the 
affinity of the complex for the nerve terminal is the product of the affinities of its 
individual subunits [51], the additional subunits contribute to a better positioning of 
the PLA2 enzyme with respect to its substrate, and/or that they reduce non-specific 
binding of the active α-subunit. Regardless, the PLA2 activity of the additional 
subunits is no longer important and therefore has been lost. As evidence, oligomeric 
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SPANs such as the heterotrimeric taipoxin and paradoxin and heterohexameric 
textilotoxin are more potent than monomeric SPANs such as notexin, notechis II-5 
and pseudexin-A in lethality studies (see [17]).   
When 4BPB was used to chemically modify the active site of P-EPTX-Aa1a, both 
the enzymatic and neurotoxic activity were significantly inhibited, suggesting His48 at 
the catalytic site is important for neurotoxic activity at the neuromuscular junction. 
This loss of neurotoxicity following alkylation with 4BPB has been previously noted 
with other SPANs [35, 52, 53], although it may result from conformational changes in 
the toxin and an altered ability to form high affinity interactions with its specific 
binding protein target [54]. Nevertheless, recent studies using a single H48Q point 
mutation at the active site of the neurotoxic SPAN OS2, unlikely to cause any 
structural perturbations at the interfacial surface, completely inhibited activity in the 
CBCNM preparation but only reduced lethality by icv injection by 16-fold [55]. This 
finding supports the idea that sPLA2 activity is important for neurotoxicity at the 
neuromuscular junction but not for central neurotoxicity. 
Further support that P-EPTX-Aa1a is a SPAN complex was provided by the 
ability of P-EPTX-Aa1a to induce fade in tetanic tension as has been previously 
reported for a number of SPAN complexes [36], but not postsynaptic snake 〈-
neurotoxins [56], during the development of neuromuscular blockade. This is 
hypothesised to result from a block of prejunctional α3β2 cholinergic receptors that 
normally mediate autofacilitation of ACh release during high frequency stimulation at 
the neuromuscular junction [57]. Conversely, tetanic fade may also result from a 
block of prejunctional adenosine A2 receptors previously shown to enhance 
neurotransmitter release [58]. Interestingly, agents that block A2-mediated 
enhancement of ACh release have a very slow timecourse of action which may go 
some way to explain the enhanced degree of tetanic fade at lower concentrations of 
P-EPTX-Aa1a, presumably resulting from a slower timecourse of neuromuscular 
blockade. Of course tetanic fade may be the consequence of the external or internal 
mechanisms to interfere with synaptic vesicle release and recycling seen with SPANs 
(for a review see [59]). Regardless of the mechanism(s) that produces tetanic fade, it 
is a clinically important phenomenon that no doubt contributes to muscle fatigue in 
envenomed patients, particularly if the safety factor for neurotransmission has been 
compromised due to slowly developing neuromuscular blockade.  
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We investigated the efficacy of the polysulfonated naphthylurea anti-
trypanosomal drug suramin to reverse neuromuscular blockade as it has been 
previously shown to inhibit the myotoxic and neurotoxic effect of bothropstoxin-I [37]. 
Being a strongly acidic polysulfonated substance, it may neutralise the sPLA2 
neurotoxic activity by forming acid-base complexes, as seen with other polyanionic 
compounds such as heparin [60]. Suramin has been proven effective in prolonging 
time to paralysis with the presynaptic neurotoxins ®-bungarotoxin and crotoxin [38]. 
Preincubation with both monovalent death adder antivenom and suramin were 
effective in the prevention or significant delay of neurotoxicity, respectively. However, 
reversal of neurotoxicity with antivenom and suramin had varying degrees of 
effectiveness. Considering the partial effectiveness of suramin in slowing the onset of 
toxicity, this may be a complimentary treatment to antivenom to prevent delayed 
onset toxicity in death adder envenomation. Importantly, however, suramin has 
shown no effectiveness against postsynaptic α-neurotoxins such as 〈-bungarotoxin 
[38], and is likely to have little effect against the postsynaptic 〈-neurotoxins previously 
identified in A. antarcticus venom (see [17] for a review).  
In summary, P-EPTX-Aa1a from A. antarcticus (NSW) venom shares similar 
overall complex and subunit mass, degree of glycosylation, neurotoxicity, pattern of 
sPLA2 activity and sequence homology to the subunits of other high molecular mass 
heterotrimeric SPAN complexes. In particular, P-EPTX-Aa1a displays the highest 
overall homology with taipoxin and cannitoxin, from the coastal and Papuan taipan, 
respectively, belonging to same Acanthophiinae subfamily as Acanthophis spp. 
Importantly, while early preincubation of antivenom prevented the onset of 
neurotoxicity, late administration of antivenom (at t90) failed to neutralize the in vitro 
neurotoxicity of P-EPTX-Aa1a. Therefore, since A. antarcticus (NSW) venom 
contains a potent irreversible SPAN, clinicians may need to be attentive of possible 
presynaptic neurotoxicity following envenomation by this snake and most likely many 
other Acanthophis spp. [21]. Therefore early intervention with antivenom is critically 
important in preventing severe prolonged envenomation from A. antarcticus and 
other Australo-Papuan death adders. 
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Fig. 1. Effects of P-EPTX-Aa1a on neuromuscular transmission in the chick biventer-
cervicis nerve-muscle preparation. (A) Rapid inhibition of indirectly-stimulated (nerve-
evoked) fast twitch contractions by 10 µg/ml whole A. antarcticus (NSW variant) 
venom (closed circles, n = 2), with no significant changes in twitch tension in time-
matched controls (open triangles, n = 3). Note the split x-axis. (B) Concentration-
dependent inhibition of indirectly-stimulated fast twitch contractions by P-EPTX-Aa1a 
(55 nM, closed squares, n = 4; 222 nM, closed circles, n = 4). Addition of 5 U/ml 
monovalent death adder antivenom 10 min prior to application of 222 nM P-EPTX-
Aa1a successfully prevented onset of toxicity (gray circles, n = 4), whereas 
antivenom applied at t90 failed to reverse the inhibition of twitch contractions (open 
circles, n = 4). (C) Lack of effect of 222 nM P-EPTX-Aa1a on twitch contractions 
evoked by direct muscle stimulation (closed circles, n = 4), in comparison to time-
matched controls (open triangles, n = 4). All muscle contractions were recorded in 
the presence of 10 µM d-tubocurarine to prevent any effects of nerve-evoked release 
of ACh. (D) Effect of venom and P-EPTX-Aa1a on contractile responses to 
exogenous ACh, CCh and KCl. Data shows the percentage of control slow fibre 
 B. Blacklow et al./Biochemical Pharmacology  28 
contracture responses to exogenous agonists after complete inhibition of twitch 
contractions by 10 µg/ml venom (closed bars, n = 4) or 222 nM toxin alone (open 
bars, n = 4), or following application of 5 U/ml antivenom at t90 (thick gray striped 
bars, n = 4) or 0.3 mM suramin (black striped bars, n = 4). In the case of 5 U/ml 
antivenom preincubated 10 min prior to addition of 222 nM P-EPTX-Aa1a (thin gray 
striped bars, n = 4), data was recorded at 300 min. Note that only whole venom 
completely inhibited responses to ACh and CCh. Data represent the mean ± SEM. 
**p < 0.01, ***p < 0.001, significantly different from control response, one-way 
ANOVA. For clarity, only data points recorded every 4 min are displayed in panels B 
and C. 
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Fig. 2. Separation of the P-EPTX-Aa1a complex under non-reducing conditions. (A) 
Representative size-exclusion FPLC chromatogram of Acanthophis antarcticus 
(NSW variant) venom employing a Superdex G-75 column with an isocratic flow of 
0.1 M ammonium acetate (pH 6.8) at 0.75 ml/min. The shaded fraction, 
corresponding to P-EPTX-Aa1a, was collected for further characterisation. (B) 
Determination of the molecular mass of P-EPTX-Aa1a. Log molecular weight versus 
retention ration (Ve / Vo) standard curve for the calibration of the Superdex G-75 
column using a series of molecular weight standards. The molecular mass of P-
EPTX-Aa1a was determined to be ca. 43 kDa. 
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Fig. 3. P-EPTX-Aa1a produces both triphasic changes in twitch tension and tetanic 
fade during neuromuscular blockade in the CBCNM preparation. (A) Inhibition of 
indirectly-stimulated fast twitch contractions by 222 nM P-EPTX-Aa1a with (open 
circles, n = 3), and without (closed circles, n = 4), a reduction in quantal content using 
9–17 mM [Mg2+]o. The [Mg2+]o was titrated to achieve 10-30% of control twitch 
contractions. Note the triphasic action evident following incubation with raised [Mg2+], 
typical of SPANs. (B) Representative tension traces showing increasing degrees of 
tetanic fade during 3 sec 50 Hz tetanic trains in the course of the development of 
neuromuscular blockade by 55 nM P-EPTX-Aa1a. Note the change in calibration in 
the lower two panels at 50 and 75% neuromuscular blockade. (C) Comparison of the 
action of P-EPTX-Aa1a (55 nM, closed bars, n = 4; 222 nM, gray bars, n = 3) with 
taipoxin (55 nM, open bars, n = 4) and d-tubocurarine (1 µM, striped bars, n = 4). 
Percent tetanic fade was calculated according to Eq. 1 in Material and Methods. Data 
represent the mean ± SEM. 
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Fig. 4. Neutralisation and reversibility of toxin-induced neuromuscular blockade by 
suramin in the CBCNM preparation. Suramin preincubated for 10 mins prior to the 
addition of 222 nM P-EPTX-Aa1a (closed squares, n = 6) significantly delayed the 
onset of neurotoxicity. However suramin applied at t50 (open squares, n = 4) or at 30 
mins following washout of the toxin (see arrow, gray squares, n = 4) prolonged, but 
did not prevent, neuromuscular blockade. 222 nM P-EPTX-Aa1a (closed circles, n = 
4) is included for comparison. Note the split x-axis. Data represent the mean ± SEM. 
For clarity, only data points recorded every 4 min are displayed. 
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Fig. 5. Isolation and mass determination of P-EPTX-Aa1a subunits. (A) Purification of 
P-EPTX-Aa1a into component subunits using C18 reverse-phase HPLC employing 
an acetonitrile/TFA gradient. A representative chromatogram at 214 nm is shown. 
Subunits are labelled 〈, β and ©. (B-C) ESI-Q-TOF mass spectrometry, showing 
deconvoluted spectra of the α-subunit (panel B, 13,809 Da) and β-subunit (panel C, 
13,516 Da). (D) MALDI-TOF mass spectrometry of the γ-subunit showing a spectrum 
consistent with heterogeneous glycosylation, with a nominal mass of 17,373 Da. The 
sum of masses is 44,698 Da, which is consistent with the estimated mass from size-
exclusion chromatography. 
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Fig. 6. Sequence alignment of P-EPTX-Aa1a subunits (A) Alignment of the three 
subunits of P-EPTX-Aa1a. (B) Alignment of individual P-EPTX-Aa1a subunits with 
known sequences of other snake sPLA2 enzymes and neurotoxins. Conserved 
residues are boxed in gray while conservative substitutions are shown in grey italic 
text. Percentage identity (%I) is relative to each respective P-EPTX-Aa1a subunit 
while percentage homology (%H) includes conservatively substituted residues. ‘ID’ 
indicates the UniprotKB/SwissProt ID code or source reference. ‘Species’ refers to 
the venom source. 
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Fig. 7. Neurotoxicity of individual P-EPTX-Aa1a subunits in the CBCNM preparation. 
Inhibition of indirectly-stimulated fast twitch contractions by the (A) individual 〈-, β-, 
and ©-subunits of P-EPTX-Aa1a subunits (740 nM, squares) and (B) equimolar 
combinations of two (triangles) or three (closed circles) subunits at 150 nM. Data 
represents the mean ± SEM of 4 experiments. (C) Effect of P-EPTX-Aa1a subunits 
(individual and recombined) on contractile responses to exogenous ACh, CCh and 
KCl. Data shows the percentage of control slow fibre contracture responses to 
exogenous agonists after complete inhibition by toxin or, in the case of subunits and 
recombinations that did not result in complete blockade, at 300 min. Data represent 
the mean ± SEM of 4 experiments. *p < 0.05, **p < 0.01, significantly different from 
control response, one-way ANOVA. For clarity, only data points recorded every 4 min 
are displayed in panels A and B. 
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Fig. 8. PLA2 activity of whole venom, toxin and subunits and neurotoxicity of 
chemically-modified toxin. (A) PLA2 activity of whole Acanthophis antarcticus (NSW) 
venom (open bar, n = 6), P-EPTX-Aa1a (closed bar, n = 4) and its three subunits 
(striped bars, n = 3–6), and 4BPB-modified P-EPTX-Aa1a (stippled bar, n = 1) as 
determined by the sPLA2 assay kit. Bee (Apis mellifera) venom (left hand bar n = 18) 
was used as a positive control. (B) Alkylated P-EPTX-Aa1a (open circles, n = 4), 
produced by chemical-modification with 4-bromophenacyl bromide (4BPB), failed to 
inhibited indirectly-stimulated fast twitch contractions in the CBCNM preparation 
when compared to 4BPB vehicle controls (open triangles, n = 4). 222 nM P-EPTX-
Aa1a (closed circles, n = 4) is included for comparison. Data represent the mean ± 
SEM. For clarity, only data points recorded every 4 min are displayed in panel B. 
